This page shows the latest Portola news and features for those working in and with pharma, biotech and healthcare.
There was a raft of other significant recommendations from the CHMP at its latest meeting, including one for Portola’s Ondexxya (andexanet alfa), which if fully approved by the EMA will
The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’ osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS)
There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos
Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... Now, it seems that while applications for andexanet alfa may be getting back on track, it will likely be
The agency said that it also needs more time to complete its review of certain clinical amendments to Portola's post-marketing commitments that were submitted recently. ... Shares in Portola plunged on news of the FDA rejection, and the company is
However, competition is also coming from rivals such as Portola Pharmaceuticals, which is currently undertaking phase III trials of andexanet alfa, which has shown to reverse the effect of other
More from news
Approximately 4 fully matching, plus 10 partially matching documents found.
Licence, collaboration. 237.5. Portola Pharmaceuticals/ HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).
merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).
Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Portola is also developing PRT 064445, which is an
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
He joins the Palma-headquartered company from Portola Pharmaceuticals, where he served as a senior vice president and head of clinical development. ... Prior to his time at Portola, Dr Gold was head of clinical development at Reata Pharmaceuticals and
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...